SGLT-2-话题@MedSci - 梅斯（MedSci）

#SGLT-2#

39篇内容 | 1726人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2081978, encodeId=e4e120819e849, content=<a href='/topic/show?id=acf116218e6' target=_blank style='color:#2F92EE;'>#SGLT-2#</a>, objectTitle=JACC：SGLT-2抑制剂可否降低2型糖尿病患者的心血管事件风险？, objectType=article, longId=144604, objectId=dfa914460422, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dfa914460422, replyNumber=0, likeNumber=72, createdTime=2019-03-07, rootId=0, userName=fmq_28614553, userId=0a3a2500014, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dfa914460422, moduleTitle=JACC：SGLT-2抑制剂可否降低2型糖尿病患者的心血管事件风险？, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=dfa914460422)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2081981, encodeId=69052081981a8, content=<a href='/topic/show?id=acf116218e6' target=_blank style='color:#2F92EE;'>#SGLT-2#</a>, objectTitle=JAMA Intern Med：SGLT-2抑制剂增加2型糖尿病患者截肢风险？, objectType=article, longId=149241, objectId=d458149241bb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d458149241bb, replyNumber=0, likeNumber=83, createdTime=2019-02-21, rootId=0, userName=fmq_28614553, userId=0a3a2500014, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d458149241bb, moduleTitle=JAMA Intern Med：SGLT-2抑制剂增加2型糖尿病患者截肢风险？, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=d458149241bb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2081979, encodeId=d21320819e93b, content=<a href='/topic/show?id=acf116218e6' target=_blank style='color:#2F92EE;'>#SGLT-2#</a>, objectTitle=JAMA Intern Med：SGLT-2抑制剂增加糖尿病患者下肢截肢风险, objectType=article, longId=146618, objectId=28f4146618a8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=28f4146618a8, replyNumber=0, likeNumber=80, createdTime=2018-12-08, rootId=0, userName=fmq_28614553, userId=0a3a2500014, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=28f4146618a8, moduleTitle=JAMA Intern Med：SGLT-2抑制剂增加糖尿病患者下肢截肢风险, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=28f4146618a8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2081975, encodeId=716420819e5f5, content=<a href='/topic/show?id=acf116218e6' target=_blank style='color:#2F92EE;'>#SGLT-2#</a>, objectTitle=JACC：SGLT-2I能明显降低患者死亡和心衰发生风险, objectType=article, longId=139466, objectId=ec421394663b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ec421394663b, replyNumber=0, likeNumber=69, createdTime=2018-05-31, rootId=0, userName=fmq_28614553, userId=0a3a2500014, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ec421394663b, moduleTitle=JACC：SGLT-2I能明显降低患者死亡和心衰发生风险, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=ec421394663b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2081972, encodeId=baad20819e2bd, content=<a href='/topic/show?id=acf116218e6' target=_blank style='color:#2F92EE;'>#SGLT-2#</a>, objectTitle=Diabetes Obes Metab：治疗2型糖尿病 SGLT-2is或比DPP-4is更胜一筹, objectType=article, longId=128540, objectId=2fed12854081, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2fed12854081, replyNumber=0, likeNumber=67, createdTime=2018-08-03, rootId=0, userName=fmq_28614553, userId=0a3a2500014, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2fed12854081, moduleTitle=Diabetes Obes Metab：治疗2型糖尿病 SGLT-2is或比DPP-4is更胜一筹, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=2fed12854081)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2081974, encodeId=e6fa20819e451, content=<a href='/topic/show?id=acf116218e6' target=_blank style='color:#2F92EE;'>#SGLT-2#</a>, objectTitle=Diabetes Obes Metab：T2DM患者进行DPP-4抑制与SGLT-2抑制对胰高血糖素的影响！, objectType=article, longId=131332, objectId=476e131332d6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=476e131332d6, replyNumber=0, likeNumber=85, createdTime=2018-11-02, rootId=0, userName=fmq_28614553, userId=0a3a2500014, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=476e131332d6, moduleTitle=Diabetes Obes Metab：T2DM患者进行DPP-4抑制与SGLT-2抑制对胰高血糖素的影响！, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=476e131332d6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2081973, encodeId=320520819e3d4, content=<a href='/topic/show?id=acf116218e6' target=_blank style='color:#2F92EE;'>#SGLT-2#</a>, objectTitle=Diabetes Obes Metab：SGLT-2抑制剂与下肢截肢风险！, objectType=article, longId=129835, objectId=b96412983500, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b96412983500, replyNumber=0, likeNumber=77, createdTime=2018-12-30, rootId=0, userName=fmq_28614553, userId=0a3a2500014, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b96412983500, moduleTitle=Diabetes Obes Metab：SGLT-2抑制剂与下肢截肢风险！, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=b96412983500)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2081971, encodeId=358720819e126, content=<a href='/topic/show?id=acf116218e6' target=_blank style='color:#2F92EE;'>#SGLT-2#</a>, objectTitle=Circulation：2型糖尿病患者初始SGLT-2抑制剂治疗获益良多, objectType=article, longId=111182, objectId=d149111182b8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d149111182b8, replyNumber=0, likeNumber=63, createdTime=2018-05-27, rootId=0, userName=fmq_28614553, userId=0a3a2500014, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d149111182b8, moduleTitle=Circulation：2型糖尿病患者初始SGLT-2抑制剂治疗获益良多, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=d149111182b8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2081969, encodeId=eb0220819695d, content=<a href='/topic/show?id=acf116218e6' target=_blank style='color:#2F92EE;'>#SGLT-2#</a>, objectTitle=Circulation：SGLT-2抑制剂与其他降糖药对患者心脏衰竭和死亡风险的影响, objectType=article, longId=99260, objectId=9f869926077, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9f869926077, replyNumber=0, likeNumber=67, createdTime=2018-02-16, rootId=0, userName=fmq_28614553, userId=0a3a2500014, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9f869926077, moduleTitle=Circulation：SGLT-2抑制剂与其他降糖药对患者心脏衰竭和死亡风险的影响, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=9f869926077)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2081970, encodeId=a9a320819e00c, content=<a href='/topic/show?id=acf116218e6' target=_blank style='color:#2F92EE;'>#SGLT-2#</a>, objectTitle=Diabetes Obes Metab：2型糖尿病患者采用DPP-4is和SGLT-2is治疗疗效和安全性比较！, objectType=article, longId=103968, objectId=8f33103968a3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8f33103968a3, replyNumber=0, likeNumber=65, createdTime=2017-11-01, rootId=0, userName=fmq_28614553, userId=0a3a2500014, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8f33103968a3, moduleTitle=Diabetes Obes Metab：2型糖尿病患者采用DPP-4is和SGLT-2is治疗疗效和安全性比较！, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=8f33103968a3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2081966, encodeId=a3c8208196672, content=<a href='/topic/show?id=acf116218e6' target=_blank style='color:#2F92EE;'>#SGLT-2#</a>, objectTitle=阿斯利康降糖药saxa/dapa（沙格列汀/达格列净）获欧盟CHMP支持批准，将成欧洲DPP-4i/SGLT-2i降糖药, objectType=article, longId=69403, objectId=04f76940319, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=04f76940319, replyNumber=0, likeNumber=95, createdTime=2016-09-16, rootId=0, userName=fmq_28614553, userId=0a3a2500014, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=04f76940319, moduleTitle=阿斯利康降糖药saxa/dapa（沙格列汀/达格列净）获欧盟CHMP支持批准，将成欧洲DPP-4i/SGLT-2i降糖药, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=04f76940319)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2081964, encodeId=8d26208196497, content=<a href='/topic/show?id=acf116218e6' target=_blank style='color:#2F92EE;'>#SGLT-2#</a>, objectTitle=CDS 2015：纪立农教授公布SGLT-2抑制剂心血管终点（Empa-REG OT 研究）, objectType=article, longId=60553, objectId=902360553c9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=902360553c9, replyNumber=0, likeNumber=66, createdTime=2016-01-26, rootId=0, userName=fmq_28614553, userId=0a3a2500014, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=902360553c9, moduleTitle=CDS 2015：纪立农教授公布SGLT-2抑制剂心血管终点（Empa-REG OT 研究）, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=902360553c9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2081968, encodeId=e5ac20819682d, content=<a href='/topic/show?id=acf116218e6' target=_blank style='color:#2F92EE;'>#SGLT-2#</a>, objectTitle=EASD 2016：阿斯利康2型糖尿病组合疗法Bydureon/Forxiga（GLP-1RA/SGLT-2i）III期临床显著降低血糖水平、体重、收缩压, objectType=article, longId=78308, objectId=7164e8308d1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7164e8308d1, replyNumber=0, likeNumber=81, createdTime=2017-08-16, rootId=0, userName=fmq_28614553, userId=0a3a2500014, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7164e8308d1, moduleTitle=EASD 2016：阿斯利康2型糖尿病组合疗法Bydureon/Forxiga（GLP-1RA/SGLT-2i）III期临床显著降低血糖水平、体重、收缩压, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=7164e8308d1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2081963, encodeId=03842081963b3, content=<a href='/topic/show?id=acf116218e6' target=_blank style='color:#2F92EE;'>#SGLT-2#</a>, objectTitle=郭艺芳：SGLT-2抑制剂——具有降糖作用的降压药, objectType=article, longId=60091, objectId=38b0600912e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=38b0600912e, replyNumber=0, likeNumber=70, createdTime=2016-08-31, rootId=0, userName=fmq_28614553, userId=0a3a2500014, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=38b0600912e, moduleTitle=郭艺芳：SGLT-2抑制剂——具有降糖作用的降压药, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=38b0600912e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2081967, encodeId=b7b1208196e42, content=<a href='/topic/show?id=acf116218e6' target=_blank style='color:#2F92EE;'>#SGLT-2#</a>, objectTitle=本周糖尿病重磅：强生降糖药INVOKAMET获FDA批准一线治疗2型糖尿病，英国NICE推荐3种SGLT-2降糖药, objectType=article, longId=69405, objectId=846b694053d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=846b694053d, replyNumber=0, likeNumber=67, createdTime=2017-05-10, rootId=0, userName=fmq_28614553, userId=0a3a2500014, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=846b694053d, moduleTitle=本周糖尿病重磅：强生降糖药INVOKAMET获FDA批准一线治疗2型糖尿病，英国NICE推荐3种SGLT-2降糖药, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=846b694053d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2081965, encodeId=d2b3208196563, content=<a href='/topic/show?id=acf116218e6' target=_blank style='color:#2F92EE;'>#SGLT-2#</a>, objectTitle=CDS 2015：洪天配解读DPP-4抑制剂与SGLT-2抑制剂在糖尿病治疗中的协同作用, objectType=article, longId=60556, objectId=f8216055671, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f8216055671, replyNumber=0, likeNumber=69, createdTime=2016-05-17, rootId=0, userName=fmq_28614553, userId=0a3a2500014, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f8216055671, moduleTitle=CDS 2015：洪天配解读DPP-4抑制剂与SGLT-2抑制剂在糖尿病治疗中的协同作用, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=f8216055671)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2081962, encodeId=9a2520819620f, content=<a href='/topic/show?id=acf116218e6' target=_blank style='color:#2F92EE;'>#SGLT-2#</a>, objectTitle=礼来SGLT-2抑制剂闪亮登场——勃林格-礼来联盟美国推出降糖新药Jardiance, objectType=article, longId=39710, objectId=b27f39e10a3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b27f39e10a3, replyNumber=0, likeNumber=70, createdTime=2015-01-15, rootId=0, userName=fmq_28614553, userId=0a3a2500014, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b27f39e10a3, moduleTitle=礼来SGLT-2抑制剂闪亮登场——勃林格-礼来联盟美国推出降糖新药Jardiance, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=b27f39e10a3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2081961, encodeId=b863208196149, content=<a href='/topic/show?id=acf116218e6' target=_blank style='color:#2F92EE;'>#SGLT-2#</a>, objectTitle=Diabetes Care：SGLT-2抑制剂Empagliflozin添加胰岛素控制不佳的肥胖T2DM患者取得较好疗效（EMPA-REG MDI研究）, objectType=article, longId=36771, objectId=40bf36e716f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=40bf36e716f, replyNumber=0, likeNumber=57, createdTime=2014-07-20, rootId=0, userName=fmq_28614553, userId=0a3a2500014, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=40bf36e716f, moduleTitle=Diabetes Care：SGLT-2抑制剂Empagliflozin添加胰岛素控制不佳的肥胖T2DM患者取得较好疗效（EMPA-REG MDI研究）, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=40bf36e716f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2081960, encodeId=b73b208196025, content=<a href='/topic/show?id=acf116218e6' target=_blank style='color:#2F92EE;'>#SGLT-2#</a>, objectTitle=EMA推荐糖尿病新药Vokanamet（SGLT-2阻断剂）上市, objectType=article, longId=31312, objectId=aac931312ad, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=aac931312ad, replyNumber=0, likeNumber=77, createdTime=2014-07-04, rootId=0, userName=fmq_28614553, userId=0a3a2500014, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aac931312ad, moduleTitle=EMA推荐糖尿病新药Vokanamet（SGLT-2阻断剂）上市, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=aac931312ad)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

SGLT-2

2020-05-29

fmq_28614553 (审核中...)

前往app查看评论内容

#SGLT-2#

JACC：SGLT-2抑制剂可否降低2型糖尿病患者的心血管事件风险？

2019-03-07

fmq_28614553 (审核中...)

前往app查看评论内容

#SGLT-2#

JAMA Intern Med：SGLT-2抑制剂增加2型糖尿病患者截肢风险？

2019-02-21

fmq_28614553 (审核中...)

前往app查看评论内容

#SGLT-2#

JAMA Intern Med：SGLT-2抑制剂增加糖尿病患者下肢截肢风险

2018-12-08

fmq_28614553 (审核中...)

前往app查看评论内容

#SGLT-2#

JACC：SGLT-2I能明显降低患者死亡和心衰发生风险

2018-05-31

fmq_28614553 (审核中...)

前往app查看评论内容

#SGLT-2#

Diabetes Obes Metab：治疗2型糖尿病 SGLT-2is或比DPP-4is更胜一筹

2018-08-03

fmq_28614553 (审核中...)

前往app查看评论内容

#SGLT-2#

Diabetes Obes Metab：T2DM患者进行DPP-4抑制与SGLT-2抑制对胰高血糖素的影响！

2018-11-02

fmq_28614553 (审核中...)

前往app查看评论内容

#SGLT-2#

Diabetes Obes Metab：SGLT-2抑制剂与下肢截肢风险！

2018-12-30

fmq_28614553 (审核中...)

前往app查看评论内容

#SGLT-2#

Circulation：2型糖尿病患者初始SGLT-2抑制剂治疗获益良多

2018-05-27

fmq_28614553 (审核中...)

前往app查看评论内容

#SGLT-2#

Circulation：SGLT-2抑制剂与其他降糖药对患者心脏衰竭和死亡风险的影响

2018-02-16

fmq_28614553 (审核中...)

前往app查看评论内容

#SGLT-2#

Diabetes Obes Metab：2型糖尿病患者采用DPP-4is和SGLT-2is治疗疗效和安全性比较！

2017-11-01

fmq_28614553 (审核中...)

前往app查看评论内容

#SGLT-2#

阿斯利康降糖药saxa/dapa（沙格列汀/达格列净）获欧盟CHMP支持批准，将成欧洲DPP-4i/SGLT-2i降糖药

2016-09-16

fmq_28614553 (审核中...)

前往app查看评论内容

#SGLT-2#

CDS 2015：纪立农教授公布SGLT-2抑制剂心血管终点（Empa-REG OT 研究）

2016-01-26

fmq_28614553 (审核中...)

前往app查看评论内容

#SGLT-2#

EASD 2016：阿斯利康2型糖尿病组合疗法Bydureon/Forxiga（GLP-1RA/SGLT-2i）III期临床显著降低血糖水平、体重、收缩压

2017-08-16

fmq_28614553 (审核中...)

前往app查看评论内容

#SGLT-2#

郭艺芳：SGLT-2抑制剂——具有降糖作用的降压药

2016-08-31

fmq_28614553 (审核中...)

前往app查看评论内容

#SGLT-2#

本周糖尿病重磅：强生降糖药INVOKAMET获FDA批准一线治疗2型糖尿病，英国NICE推荐3种SGLT-2降糖药

2017-05-10

fmq_28614553 (审核中...)

前往app查看评论内容

#SGLT-2#

CDS 2015：洪天配解读DPP-4抑制剂与SGLT-2抑制剂在糖尿病治疗中的协同作用

2016-05-17

fmq_28614553 (审核中...)

前往app查看评论内容

#SGLT-2#

礼来SGLT-2抑制剂闪亮登场——勃林格-礼来联盟美国推出降糖新药Jardiance

2015-01-15

fmq_28614553 (审核中...)

前往app查看评论内容

#SGLT-2#

Diabetes Care：SGLT-2抑制剂Empagliflozin添加胰岛素控制不佳的肥胖T2DM患者取得较好疗效（EMPA-REG MDI研究）

2014-07-20

fmq_28614553 (审核中...)

前往app查看评论内容

#SGLT-2#

EMA推荐糖尿病新药Vokanamet（SGLT-2阻断剂）上市

2014-07-04

科室
- - 订阅+
  - 更多科室
工具
服务